Testosterone Deficiency in Men Ron Rothenberg MD
|
|
- Ashley McCormick
- 6 years ago
- Views:
Transcription
1 Testosterone Deficiency in Men Ron Rothenberg MD Relevant financial relationships in the past twelve months by presenter or spouse/partner: NA Equipment: NA Speakers Bureau: NA Stock Shareholder: NA Grant/Research Support: NA Consultant: NA Status of FDA devices used for the material being presented NA Status of off-label use of devices, drugs or other materials that constitute the subject of this presentation NA
2 Testosterone Deficiency in Men Ron Rothenberg MD
3 You can download all slides at CaliforniaHealthSpan.com
4 l We age because our hormones decline, our hormones don t decline because we age Testosterone replacement therapy is safe and can provide dramatic benefits Testosterone decreases inflammation
5 Testosterone Deficiency=Male Menopause=Andropause=Androgen Deficiency Aging Male = Hypogonadism l Less sudden in onset than female menopause l Just as severe in long term consequences l The cause. l Decreased bioavailable TESTOSTERONE +
6 Testosterone Deficiency l Increased aging of heart and circulation Increased MI s and CVA s Decreased hemodynamic function l Increased brain aging Decreased memory Decreased intelligence Increased Dementia, Alzheimer's
7 Testosterone Deficiency l Loss of drive and competitive edge l Stiffness and pain in muscles and joints l Falling level of fitness l Decreased effectiveness of workouts
8 Testosterone Deficiency- Deteriorating body composition l Sarcopenia Less muscle, more fat l Osteoporosis l Anemia Testosterone Deficiency Increased Cancer
9 Testosterone Deficiency l Fatigue, Tiredness l Depression, Mood changes l Irritability l Dysphoria l Reduced libido and potency Decreased desire and fantasies Decreased morning erections Decreased erectile tension Longer recovery time between orgasms Decreased intensity of orgasms
10 Low Testosterone is a deficiency disease l Half of healthy men between the ages of yr will have a BT level below the lowest level seen in healthy men who are yr of age l Korenman SG, Morley JE, Mooradian AD, et al Secondary hypogonadism in older men: its relationship to impotence. J Clin Endocrinol Metab. 71:
11 Testosterone Deficiency l T decline: l Begins early 30 y/o l years old 30% decrease in Total T 50% decrease in bio-available T l Severe T deficiency can start very early in 20 s
12 Testosterone getting lower every year l Travison TG et al. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab Oct 24
13 Phthalates and Decreased T l Plasticizers found in environment, medications, plastic tubing- hormone disruptors l Phthalates significantly reduced T in both sexes. Women and men ages years. Boys 6 12 years old: l 29% reduction in T l Meeker et al. Urinary Phthalate Metabolites Are Associated With decreased Serum Testosterone in Men, Women, and Children From NHANES. J Clin Endocrinol Metab Aug 14
14 Testosterone Deficiency is a lethal disease l Diabetes, Metabolic syndrome l Brain l Heart l Frailty syndrome l Bone l Inflammation l Cancer
15 Testosterone Treatment 56% less mortality l 83,000 VA men > 50 y/o low testosterone l Normalized-TRT treated and test normalized l Non-normalized-TRT treated and test not normalized l No TRT not treated l Sharma, R et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J Aug 6
16 Normalized-TRT vs. No TRT Hazard Ratios l All cause mortality.44 CI p< l Risk of MI.76 CI p< l Risk of Stroke.64 CI p< l Significant but higher hazard ratios Normalized-TRT vs. Non-normalized-TRT l No difference Non-normalized-TRT vs. No TRT l Sharma, R et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J Aug 6
17 Testosterone treatment and Mortality l 1000 male veterans, > 40 years old, 4 years Rx l Total test < 250 l 400 treated with testosterone l Mortality treated 10% vs. 20% controls l p < l Decreased risk of death l Hazard ratio 0.61 l 95% confidence interval , p =.008 l Prostate CA treated 1.6% l untreated 2.0 l Shores MM et al. Testosterone Treatment and Mortality in Men with Low Testosterone Levels. J Clin Endocrinol Metab Apr
18 Ron Rothenberg 2016 Vitamin D Red inhibits Yellow activates Unified Theory of Wellness CRP Resveratrol EPC s Chronic Inflammation Is the Cause and the Effect of the Diseases of Aging Stress Infection Depression High Glucose and Insulin Hormone Decline Lack of Exercise Aging High Homocysteine Trans Fats Nutrition Glucose and Insulin control Inflammatory Cytokines High Homocysteine B vits Control insulin. Less omega 6 Less Diet Arachadonic Acute phase proteins CRP, Fibrinogen EPA, DHA High Glucose Anti-Inflam Diet Anti-Inflammatory Cytokines Adipocytes Adhesion molecules VCAM1, ICAM1, MCP1, MadCAM1 Inflammatory cytokines NF Kappa Beta Inflammatory Enzymes COX, LOX Arachidonic acid Coxibs block vioxx ASA PGI2=prostacyclin good eicosanoids Good Eicosanoids aging GH E2 IBD EPA cancer Diabetic Retinopathy ASCVD P4 ASCVD Pro-oxidants Viral Infections SRIF EPA Anti-oxidants Glutathione DHEA, Testosterone Melatonin EPA Bad Eicosanoids TXA2. ASCVD PGE2, LRC4 - CA Pain PGE2, LTB4 ASCVD cancer Chronic Illness Wellness GH Resveratrol IGF1 Angiotensin II PTH PGE2: Pain Cancer Skin aging p53 Phosphate RANKL Immune Magnesium Catecholamines Pain TXA2 Atherosclerosis
19 Testosterone and CV risk l Significant reduction in risk All cause mortality Cardiovascular mortality Cancer mortality l More information in presentations later today in l Hormones and the heart l Hormone myths
20 Strength and muscle function l T is major predictor of skeletal mass l Synergistic with GH and IGF-1 l Improved strength even without exercise but marked improvement with exercise l Bhasin S. The dose-dependent effects of testosterone on sexual function and on muscle mass and function. Mayo Clin Proc Jan;75 Suppl:S70-5
21 Change in fat free mass Placebo no exer. T no exer. Placebo + exer. T + exer. Change in Quad area Change in squat strength
22 Lower Free T predictive of Frailty in Older Men l Fatigue, stair climbing, walking more than 100 m, > 5 illnesses and weight loss >5 % measured in 3166 community dwelling men aged over 8 years. l Lower free T predicted frailty l Hyde, Zoe et al. Low Free Testosterone Predicts Frailty in Older Men: The Health in Men Study. JCEM 2010 Jul.Vol 95, No 7.p
23 TRT and erectile function l Libido always increased l Nitric Oxide receptors up regulated l Usually improved erectile function l May take up to 6 months l Response to Sildenafil etc improved
24 T and cognitive function l T correlated with cognitive function and TRT improves it l Alexander GM, Swerdloff RS, Wang C, et al. Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Hormones and Behavior 1998; 33(2): l Barrett-Connor E et al. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999 Oct;84(10):3681-5
25 Testosterone, LH, AD l Low Testosterone and increased LH Are established AD risk Increase beta amyloid accumulation in humans l Increased Pittsburgh B Imaging (PiB) Low T, Increased LH and positive APOE-4 allele l Verdille G et al. Associations between gonadotropins, testosterone and beta amyloid in men at risk of AD. Mol Psychiatry Jan; 19(1) l Verdille G et al. The impact of LH and testosterone on beta amyloid accumulation: Animal and human clinical studies. Horm Behav Jun 27
26 T Rx Alzheimer s l Treated group improved over 1 year l Control group deteriorated l TRT prevents the production of beta amyloid precursor protein. (in men) l Gouras GK et al. Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. Proc Natl Acad Sci U S A 2000 Feb 1;97(3): l Tan RS A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male Mar;6 (1):13-7.
27 T and mood (and erections) l Effective when psych drugs do not work in pts with low T l Cooper MA. Testosterone Replacement Therapy for Anxiety. Am J Psychiatry 157:1884, November 2000 l TRT increases nocturnal and spontaneous erections and improves mood l Burris A et al. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992 Jul-Aug;13(4):
28 T and cognitive cerebral blood flow l High Free T was associated with better performance on tests of memory, executive function, and spatial ability, and with a reduced risk for Alzheimer's disease. l Improved cerebral blood flow l Moffat SD, Resnick SM. Long-term measures of free testosterone predict regional cerebral blood flow patterns in elderly men.neurobiol Aging May 11
29 Testosterone and Cognition l Conclusion: Verbal memory - aromatization of testosterone to estradiol Spatial memory - absence of increases in estradiol l M.M. Cherrier et al. The role of aromatization in testosterone supplementation.effects on cognition in older men. Neurology. 2005; 64: l M.M. Cherrier et al. Relationship between testosterone supplementation and insulin-like growth factor-ilevels and cognition in healthy older men. Psychoneuroendocrinology 29 (2004) 65 82
30 Testosterone, Diabetes, Depression l All correlated and TRT improves Depression and Diabetes l Tully PJ et al Elucidating the Biological Mechanisms Linking Depressive Symptoms With Type 2 Diabetes in Men: The Longitudinal Effects of Inflammation, Microvascular Dysfunction, and Testosterone. Pychosom Med Feb-Mar; 78(2)
31 Testosterone and BPH/LUTS l Multiple studies: l T does not exacerbate and sometimes improves symptoms l Baas, W et al. Testosterone Replacement Therapy and BPH/ LUTS. What is the Evidence? Curr Urol Rep Jun;17(6):46.
32
33 Baas Conclusions: TRT and LUTS l Androgen receptors saturated at near castration and prostate size does not increase with TRT l Prostate size increases with age despite lowered T levels. Young men with high T levels do not have LUTS symptoms l Symptoms of BPH/LUTS do not increase with prostate size l TRT may be beneficial via T mediated nitric oxide synthase up-regulation and smooth muscle relaxation
34 l Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med Jan 29;350(5): l Pearl JA et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol.2013 Nov;190(5): l Kathrins M et al. The Relationship between Testosterone Replacement Therapy and Lower Urinary Tract Symptoms: A Systematic Review. Urology Nov 23.
35 European Study T and PCa l 1023 patients up to 17 years with TRT l Cohort Pca 54.4/10,000 pt years l Cohort Pca 30.7/10,000 pt years l Cohort Pca 0/10,000 pt years l Background prevalence 96.6/10,000 pt yrs l Conclusion- Testosterone therapy in hypogonadal men does not increase the risk of prostate cancer. l Ahmad Haider et al. Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from Five Year-median Follow-up of Three Registries. The Journal of Urology, Volume 193/Issue 1 (January 2015)
36 Prostate CA and Hormones l 3886 men with prostate cancer, 6438 controls l No associations were found between the risk of prostate cancer l Testosterone, calculated free testosterone, dehydroepiandrosterone sulfate, androstenedione, androstanediol, estradiol, calculated free estradiol l Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies Endogenous Hormones and Prostate Cancer Collaborative Group. J Natl Cancer Inst :
37 TRT and PC over 20 years l 1365 men with TRT x 20 years l Screened with PSA and DRE q 6 months l Abnormal changes with US prostate and biopsy l Conclusion: No difference in PSA, free PSA and PCa as compared to background All cancer in treatment group localized and curative Testosterone treatment and monitoring may be safer than no treatment l Feneley MR et al. Is testosterone treatment good for the Prostate? Study of safety during long term treatment. Journal of Sex Med 2012; June 6
38 History of T causes PC myth l 1941: Huggins and Hodges reported that marked reductions in T by castration or estrogen treatment caused metastatic PC to regress l Administration of exogenous T caused PC to grow. This was based on only one patient l Based on increased acid phosphatase l Multiple subsequent reports revealed no PC progression with T administration l Some men even experienced subjective improvement, such as resolution of bone pain l Morgantaler A. Testosterone and Prostate Cancer: An Historical Perspective on a Modern Myth. Eur Urol Jul 26
39 1941 l Huggins, C., Hodges, C.V. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res.1941;1:293. l
40 l Recent data have shown no apparent increase in PC rates in clinical trials of T supplementation in normal men or men at increased risk for PC l No relationship of PC risk with serum T levels in multiple longitudinal studies l No reduced risk of PC with low T. l The paradox in which castration causes PC to regress yet higher T fails to cause PC to grow l Resolved by a saturation model, in which maximal stimulation of PC is reached at relatively low levels of T
41 Morgentaler conclusion l There is not now-nor has there ever been a scientific basis for the belief that T causes PC to grow
42
43
44 <
45 Pomegranate Juice and PC l Rising PSA after surgery or radiotherapy l 8 ounces of pomegranate juice daily until disease progression l Mean PSA doubling time significantly increased with treatment from 15 months to 54 months (P < 0.001). l 12% decrease in cell proliferation l 17% increase in apoptosis l Significant reductions in oxidative state l Pantuck AJ et al. Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer. Clin Cancer Res Jul 1;12(13):
46 Antioxidants and PC l Greater intake of antioxidants (dietary and supplementation) is associated with less aggressive prostate cancer. (P<.001) l Vance TM et al. Dietary total antioxidant capacity is inversely associated with prostate cancer aggressiveness in a population-based study. Nutr Cancer Feb 4:1-11.
47 Treating with T after Radical Prostatectomy for PC l Organ confined PC l Radical Prostatectomy l PSA <0.1 after 1 year l Treated with T l No recurrences or increase in PSA l Agarwal PK et al. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol Feb;173(2):533-6.
48 TRT. Prostate Ca, Brachytherapy l TRT years after brachytherapy l Follow up years l 1 patient with transient rise of PSA <1.0 l No patient stopped TRT due to cancer recurrence or disease progression l Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer Feb 1;109(3):
49 TRT after Radiation TX for PCa l Conclusions: Testosterone therapy in men following radiation therapy for PCa was associated with a minor increase in serum PSA and a low rate of BCR l Pastuszak A et al. Testosterone Therapy after Radiation Therapy for Low, Intermediate, and High Risk Prostate Cancer. The Journal of Urology. 13 May 2015.
50 Active Prostate CA and Testosterone Therapy l 13 testosterone deficient men with untreated prostate CA l Testosterone increased 238 to 664, PSA, prostate volume unchanged l After 2.5 years - No cancer found in 54% of prostate biopsies. l No local progression or metastases l Morgantaler et al.testosterone Therapy in Men with untreated Prostate CA.J Urol 2011 Apr, (185:4)
51 Active Surveillance, Prostate CA, Testosterone Treatment l 28 men on AS with Gleason 3+3, 3+4 x 3 years treated with testosterone, 96 controls untreated l Biopsy progression in men on AS appears unaffected by T therapy over 3 years l Kacker R, Morgantaler A et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results Asian J Androl 2015 Aug 21.
52 l Morgentaler A et al. A New Era of Testosterone and Prostate Cancer: From Physiology to Clinical Implications. Eur Urol Aug 16. l Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol Jan;189(1 Suppl):S l Aversa A, Morgentaler A. The practical management of testosterone deficiency in men. Nat Rev Urol Nov;12(11):
53 Testosterone Supplementation Augments Overnight Growth Hormone Secretion l 100 mg T IM q 2 weeks x 26 weeks l Total T increased 33% l E2 increased 31% l SHBG decreased 17% l GH secretion increased 1.9 x l IGF-1 increased 22% l IGFBP-3 no change l Muniyappa R et al. Long-Term Testosterone Supplementation Augments Overnight Growth Hormone Secretion in Healthy Older Men. Am J Physiol Endocrinol Metab. 2007
54 Testosterone Treatment and Diabetes and Metabolic Syndrome l Can have dramatic effect on insulin resistance, visceral fat, blood pressure
55 Bi-directional relationship between visceral fat and testosterone: self-perpetuating cycle promoting insulin resistance.
56 Mechanisms Testosterone vs. Diabetes l Modulator of body composition - promoting myogenesis and inhibiting adipogenesis l Enhances transport of glucose into cells l Improved Endothelial function may be the basis for the reduction of BP and HR and ED l One-year TU is able to improve arterial stiffness and endothelial function l Improved Vitamin D status maybe thru up regulated 1 alpha hydroxylase and decreased adipose
57 Testosterone Induces normal pulsatile GH secretion Regulates lineage of mesenchymal pluripotent cells by promoting the myogenic lineage and inhibiting the adipogenic lineage Mobilizes lipids from the visceral fat depot which improves CV risks Increases motivation, enhancement of mood, and promotion of more energy expenditure
58 Testosterone Treatment with Metabolic Syndrome l Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol. 2014;2014: l Testosterone = 241 (mean) l Metabolic syndrome l All had nutrition and exercise counseling l T undecanoate 1000 mg q 6 weeks x2 then q 12 weeks x 60 months
59 TRT but not control group BMI 2.9 ± 1.4 P < l BMI Waist circumference 9.6± 3.8cm P < Weight 15 ± 2.8Kg P < HgA1C 1.6±0.5% P < Insulin Sensitivity 2.8 ± 0.6 P < Total/HDL-cholesterol 2.9 ± 1.5 P < Triglycerides 41 ± 25 P < l Francomano D et al.effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol. 2014: Feb 12
60 TRT but not control groupcontinued Systolic 23 ± 10mmHg P < Diastolic 16 ± 8mmHg P < Neck/Lumbar T score.5 ± 0.15gr/cm3 P < Serum 25OH Vitamin D ± 1.3ng/mL P < 0.01 TSH 0.9 ± 0.3 mui/ml P < 0.01 IGF ± 11 P < 0.01 Hematocrit +2.8 ± 0.9% P < PSA ± 0.29ng/mL P < 0.01 l Francomano D et al.effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol. 2014;2014: Feb 12
61 Lab Testing l Prostate cancer screen PSA < 4.0 PSA similar to baseline if prior values known DRE no suspicious findings of PC PSA Controversy l H and H baseline Keep Hg < 17.5 by donating or discarding blood 1-4 times a year if needed
62 Estradiol - Aromatase - DHT 5-alpha Reductase Sperm Sertoli cell Leydig cell
63 Testosterone Lab Testing Test Sex Reference Optimal Total ng/dl Male Free* ng/dl (Equilibrium dialysis) Female Male Female Bioavailable Male pg/ml Female * Free testosterone results vary with methodology direct analog (RIA) in pg/ml same ref range
64 TOTAL TESTOSTERONE T T T T T T T. T. T ALBUMIN T T T T T T SEX HORMONE BINDING GLOBULIN
65 FREE TESTOSTERONE T T T T T T T T T T T SEX HORMONE BINDING GLOBULIN T T T T ALBUMIN
66 BIOAVAILABLE TESTOSTERONE T T T T T T T T T T ALBUMIN T T T T T T SEX HORMONE BINDING GLOBULIN
67 SHBG binds T > E l nmol/l male l nmol/l female l Low SHBG associated with Insulin Resistance in men and women
68 l Increases SHBG Thyroid Estrogens Progesterone Aging Low Insulin Coffee (not decaf). Green tea, soy l Decreases SHBG Testosterone DHEA Glucocorticoids GH High Insulin
69 Low calculated Free Test - symptoms l Low cft, even in the presence of normal TT, is associated with androgen deficiencyrelated symptoms. l Lab free testosterone inaccurate. l Even the best available measurement procedures have technical and fundamental limitations l Antonio L et al. Low Free Testosterone is Associated with Hypogonadal Signs and Symptoms in Men with Normal Total Testosterone. J Clin Endocrinol Metab Feb 24
70 Free Free T calculator l freetesto.htm
71 Guys Need Estrogen Too l Higher testosterone, greater muscle size and strength l Higher estrogen, less Fat l Higher testosterone and higher estrogen, better libido and erection function l Finkelstein JS et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med Sep 12;369(11):
72 l Jankowska EA. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA May 13;301(18):
73 T Metabolites - Estradiol l E2 usually increases with increasing T l Do not let E2 get too low Optimal? pg/ml NEJM 9/2013 Finkelstein study Need E2 for fat control, libido and erectile function l Aromatase Inhibition Chrysin 250 mg BID PO Topical 50 mg/gm Zinc 50 mg per day Progesterone 5-10 mg transdermal
74 Anastrozole Anastrozole 0.5 mg 1-3 x per week l Can precisely control E2 l Do not let levels fall too low, take it easy with E2 control l E2 is necessary for brain, heart, bone, fat control, sexual function l Use with clinical symptoms only?
75 l Schmidt M, Renner C, Loffler G. Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts. J Endocrinol Sep;158(3): l Leder BZ et al. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab Mar;89(3): l Jeong, HJ et al. Inhibition of aromatase activity by flavinoids. Arch Pharm Res Jun;22(3):309-12
76 T Metabolites - DHT l DHT can increase with increasing T, especially with transdermal T l DHT does not aromatize to E2 l Is DHT evil twin of T or good androgen? l DHT needed for erectile function and anabolic effects l Not associated with Prostate CA in serum levels l Possibly associated with BPH and hair loss
77 5-alpha reductase inhibition l 5- alpha reductase and dutasteride and finasteride l PCa risk reduction? l Higher grade Pca? l Major drug intervention
78 5-alpha reductase inhibition l Neuroactive steroids - 5-allo-pregnenolone needed for neuronal repair and memory l Inhibition of 5-alpha-reductase by finasteride inhibits hippocampal neurogenesis l Contributes to the pathophysiology of depression and memory loss l Neurosteroids are potent endogenous modulators of the GABA receptor l Traish AM et al. 5- alpha-reductases in human physiology: an unfolding story. Endocr Pract Nov-Dec;18(6):
79
80 Reported side effects of finasteride and dutasteride l Impair sexual function, including sexual desire, erectile and orgasmic function l Impair NO function and can produce ED and this can be long lasting and irreversible l Depression l Do not reduce incidence of aggressive and high grade prostate cancer
81 Mild 5-alpha reductase inhibition l Saw palmetto 320 mg/day l Progesterone transdermal 5-10 mg/ day l Scaglione F et al. Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur Rev Med Pharmacol Sol May16(5)569-74
82 Progesterone men Similar levels present in men and women in follicular phase 0.5 ng/ml GABA receptor binding Improves hot flashes in men treated with leuprolide Oettel M et al. Progesterone: the forgotten hormone in men? Aging Male Sep;7(3):236-57
83 TRT - Potential Adverse effects l Major side effect Increased RBC s - Erythrocytosis l More likely with injections than creams l Phlebotomy if needed every 3 12 months l Donate or discard 1 unit when hemoglobin > 17.5
84 TRT -Potential Adverse effects l Gynecomastia- rare l Acne l Fluid retention (rare) l Does TRT accelerate male pattern hair loss? Possibly. l Possible decrease in testicular size. l Decreased sperm count
85 Subcutaneous Testosterone l CONCLUSION: Weekly subcutaneous testosterone produced serum levels that were within the normal range in 100% of patients for both peak and trough levels. l Al-Fataisi AM et al. Subcutaneous administration of testosterone. A pilot study report. Saudi Med J Dec;27(12):
86 Transdermal l Well absorbed in most men l Saliva levels may reflect intracellular effects l Serum levels usefull for monitoring l More DHT since hair follicles contain 5 alpha reductase l Steady state after 24 hours
87 Pellets l Subcutaneous pellets Minor surgical procedure Last 3 + months 75 mg pellets x 7-14
88 HCG injections l Human chorionic gonadotropin (HCG) l Polypeptide hormone produced by the human placenta l Alpha and beta sub-unit. l Alpha sub-unit is essentially identical to the alpha sub-units of LH and FSH
89 HCG l If there is no Leydig cell failure can use HCG injections units per week sub-q - divided l No decrease in testicular size or sperm count l Can use as TRT (measure free T to confirm success) or cycle with TRT every 6 months l Zitzmann M Hormone substitution in male hypogonadism Mol Cell Endocrinol 2000 Mar 30;161(1-2):73-88
90 HCG l If FSH and LH already relatively high, probably will not work l Avoids the TRT side effects of loss of testicle volume and decreased sperm count l More aromatization?
91 T Dose Men l Cream mg/day l Cypionate mg IM or SQ/ week l Pellets 75 mg x 5-15 q 3 months l HCG units per week Possible dosing: 250 units per day 1000 units twice a week T cypionate 100 mg IM on day 1 l HCG 250 units SC days 5 and 6
92 TRT A clinical specialty l Because of excessive reliance on laboratory measures of androgens and undue safety concerns, many men who could benefit from symptom relief, improvement in related clinical conditions and given preventive medical benefits remain untreated. l Carruthers M et al. Evolution of testosterone treatment over 25 years: symptom responses, endocrine profiles and cardiovascular changes. Aging Male. 2015
93
94
95
96
Hormone Replacement Therapy
Hormone Replacement Therapy What Role Should It Play With Our Patients? Noel R. Williams MD, FACOG TESTOSTERONE FOR MEN: SALVATION OR SNAKE OIL? Definition Male hypogonadism means the testicles don't produce
More informationTestosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands
Testosterone Therapy and the Prostate Frans M.J. Debruyne Professor of Urology The Netherlands TRT- Risks Prostate ( Cancer, BPH )? Cardiac? Lipids? Polycythemia Sleep apnea Gynecomastia Edema Testosterone
More informationPoint-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationHormones Nuts and Bolts. Ron Rothenberg MD
Hormones Nuts and Bolts Ron Rothenberg MD Power Point Slides All slides from my presentation will be available to you. They will be posted to website next week CaliforniaHealthspan.com Hormone Bio-Identical
More informationHypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
More informationHORMONE THERAPY IN AGING MALE ATHLETES
DISCLOSURES HORMONE THERAPY IN AGING MALE ATHLETES No relevant affiliations or financial interests When, Why and is it Safe? OBJECTIVES Summarize the benefits of optimizing hormone balance Examine the
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationDoes TRT Induce Prostate Cancer?
Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there
More informationTESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER?
TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY (TRT) Nuno Tomada, MD, PhD Department of Urology of Hospital S. João Faculty of
More informationHow to treat: TRT modalities and formulations
How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationHYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION
More informationPCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS
Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal
More informationA dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
More informationCan men on AS be treated with testosterone?
Can men on AS be treated with testosterone? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Conflicts of interest PI or member steering
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationTestosterone Therapy in Men with Hypogonadism
Testosterone Therapy in Men with Hypogonadism (Endocrine Society 2018 Guideline) Ngwe Yin, MD Assistant Clinical Professor of Medicine, UCSF Fresno Medical Education Program Disclosures None Objective
More informationManaging Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University
Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a
More informationTobias S. Kohler, MD, MPH, FACS Southern Illinois University School of Medicine AUA SMSNA Program May 7, 2016
Tobias S. Kohler, MD, MPH, FACS Southern Illinois University School of Medicine AUA SMSNA Program May 7, 2016 Abbvie Researcher/Consultant/Grant Funding Boston Scientific Researcher/Consultant/Grant Funding
More informationUpdate on diagnosis and complications of adult and elderly male hypogonadism
Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationTestosterone: Current Opinion and Controversy
Testosterone: Current Opinion and Controversy Ravi Kacker, MD Metrowest Urology (508) 655 4422 Medical Office Building at Leonard Morse Hospital Disclosures MHB Labs President and CEO of Drug Development
More informationProf Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA
Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prevailing context Increase number of men who are potential candidates for Testosterone Replacement Therapy
More information6/14/2010. GnRH=Gonadotropin-Releasing Hormone.
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
More informationAn Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health
An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY
More informationDefinition of Andropause
HORMONE REPLACEMENT THERAPY FOR MEN Thomas C. Reed R.Ph., F.A.C.A. Reed s Compounding Pharmacy 2729 E. Speedway 318-4421 reedsrx.com 7/7/2010 1 Definition of Andropause A gradual decline in sex hormone
More informationTRT and localized protate cancer
TRT and localized protate cancer Frans M. J. Debruyne Professor of Urology PRISM BRUGES Increased risk of prostate cancer with TRT? Prostate cancer Testosterone and Prostate Cancer There appears to be
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Hypogonadism: Treatment Safety and Prostate Health 2 Monitoring for Testosterone Therapy DRE 1,2 PSA Parameter Voiding/IPSS 1,2 Hemoglobin
More informationEVIDENCE SUPPORTING TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER
EVIDENCE SUPPORTING TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER Abraham Morgentaler, MD Director and Founder Men s Health Boston Associate Clinical Professor Harvard Medical School And the Urology
More informationArresting Prostate Cancer Development. By Dr. Walker
Arresting Prostate Cancer Development By Dr. Walker Objectives The many faces of prostate cancer? Discuss the pathogenesis of prostate cancer How does lifestyle impact our risk of prostate cancer? Arresting
More informationWhat Is the Low T Syndrome? Is Testosterone Supplementation Safe?
What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or
More informationMen Getting Older Will Testosterone Keep Him Young?
Men Getting Older Will Testosterone Keep Him Young? Alvin M. Matsumoto, M.D. Associate Director, GRECC V.A. Puget Sound Health Care System Professor, Department of Medicine Division of Gerontology and
More informationEvaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008
More informationLate onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
More informationMale Menopause Avoiding andropause with testosterone treatment By Edward D. Rosick
Male Menopause Avoiding andropause with testosterone treatment By Edward D. Rosick Menopause, the time in a woman s life of distinct hormonal changes, can be very stressful both on an emotional and physical
More informationDiagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ)
Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ) Alvaro Morales CM MD, Richard A. Bebb MD, Priya Manjoo MD MSc, Peter Assimakopoulos MD, John
More informationHormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index
Hormonal Health PATIENT: Sample Report TEST REF: TST-12345 Hormonal Health 0.61 0.30-1.13 ng/ml DHEA-S 91 35-430 mcg/dl tient: SAMPLE TIENT e: x: N: Sex Binding Globulin 80 18-114 nmol/l Testosterone 0.34
More informationTestosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
More informationTHINGS ARE NOT ALWAYS AS THEY APPEAR. Assume Nothing!
THINGS ARE NOT ALWAYS AS THEY APPEAR Assume Nothing! UP SIDE DOWN WORLD OF PROSTATE CANCER Paul D. Thompson, M.D. Fort Worth Texas WHAT WE THOUGHT WE KNEW AND WHAT WE KNOW TODAY FINANCIAL DISCLOSURES
More informationDisclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
More informationHypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Hypogonadism in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More informationRisk of renal side effects with ADT. E. David Crawford University of Colorado, Aurora, CO, USA
Risk of renal side effects with ADT E. David Crawford University of Colorado, Aurora, CO, USA ADT: A key treatment for advanced prostate cancer John Hunter 1780-castration 1904: First RP 1938: Acid Phos.
More informationTESTOSTERONE DEFINITION
DEFINITION A hormone that is a hydroxyl steroid ketone (C19H28O2) produced especially by the testes or made synthetically and that is responsible for inducing and maintaining male secondary sex characteristics.
More informationPRISM Bruges June Herman Leliefeld Urologist. The Netherlands
PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up
More informationRecognizing and Managing Testosterone Deficiency
Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships
More informationTherapeutic Cohort Results
Patient: SAMPLE PATIENT DOB: Sex: MRN: Menopause Plus - Salivary Profile Therapeutic Cohort Results Hormone Average Result QUINTILE DISTRIBUTION 1st 2nd 3rd 4th 5th Therapeutic Range* Estradiol (E2) 8.7
More informationRecommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men
Recommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men Bruno Lunenfeld, George Mskhalaya, Svetlana Kalinchenko, Yulia Tishova, Michael Zitzmann, Stefan
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationTEST REPORT # SB. Patient Name: Comprehensive Male Profile I Patient Phone Number: TEST NAME RESULTS 08/12/18 RANGE
TEST REPORT Ordering Provider: David Getuwell, MD 8605 SW Creekside Place Beaverton, OR 97008 Phone: 503-466-2445 Fax: 503-466-1636 Samples Received 08/15/2018 Report Date 08/20/2018 Samples Collected
More informationSexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist
Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationThe Male Andropause. What are the symptoms? What are the risks of hormone deficiencies?
The Male Andropause By: Dr. Sangeeta Pati MD, FACOG Although, the male andropause has not been widely recognized, increased medical research has turned attention to the gradual hormone decline in males
More informationGUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationFAILURE IS NOT AN OPTION HOPE IS NOT A PLAN
FAILURE IS NOT AN OPTION HOPE IS NOT A PLAN Doctors' Secrets What Men Want - Testosterone - Sharing the Secrets of Men s Health Donald M. McLeod M.D. and Philip A White M.D. CONTENTS SECTION I Introduction
More informationISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN
International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency
More informationAndroderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
More informationAn Update on Men s Health and Sexual Function
An Update on Men s Health and Sexual Function Lawrence Jenkins, MD, MBA Assistant Professor Clinical Department of Urology The Ohio State University Wexner Medical Center Outline Testosterone Deficiency
More informationNaviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes
Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes E. David Crawford, M.D. Professor of Surgery/ Urology/ Radiation Oncology University of Colorado Greetings from Colorado Disclosures Consultant:
More informationLate onset hypogonadism
Late onset hypogonadism Farrukh Javid Male Menopause Clinical AND biochemical syndrome Testosterone levels decline by 0.4-3% per year after the age of 30, as opposed to the more rapid decline that occurs
More informationManaging High Blood Pressure Naturally. Michael A. Smith, MD Life Extension s Healthy Talk Series
Managing High Blood Pressure Naturally Michael A. Smith, MD Life Extension s Healthy Talk Series Part 1 What is Blood Pressure? Blood Pressure Systole Systolic Forward Pressure 110 mmhg 70 mmhg Diastole
More informationOne Day Hormone Check
One Day Hormone Check Patient: EMILY TEST DOB: January 18, 1948 Sex: F MRN: 0000000004 Order Number: J5070009 Completed: March 07, 2014 Received: March 07, 2014 Collected: March 07, 2014 Alec Smart, ND
More informationLabrix Clinical Services, Inc.
Labrix Clinical Services, Inc. Advantages of Labrix Clinical Services, Inc. We Cater to the Healthcare Practitioner Labrix sample collection tubes are small; only 1 ml of saliva is required from the patient.
More informationTherapeutic Cohort Results
Patient: JANE DOE DOB: December 31, 1968 Sex: F MRN: Order Number: Completed: February 26, 2016 Received: February 26, 2016 Collected: February 26, 2016 One Day Hormone Check - Salivary Profile Therapeutic
More informationAlternative management of hypogonadism Tamoxifen. Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY
Alternative management of hypogonadism Tamoxifen Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY eajannini@gmail.com What hypogonadism is? What hypogonadism is? It is an empty glass The two
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone
More informationMALE HYPOGONADISM: CHOOSING THE APPROPRIATE THERAPY. Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism
MALE HYPOGONADISM: CHOOSING THE APPROPRIATE THERAPY Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism Disclosures Aromatase inhibitors & clomiphene citrate are
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel AXIRON transdermal solution FORTESTA transdermal gel NATESTO nasal gel STRIANT buccal mucoadhesive
More informationComplete Medical History
Lab Results for Ben Greenfield Last Test Date: Your medical history is not complete. Complete Medical History Complete Medical History What's Next Blood Draw Blood draw scheduled Complete your medical
More informationOne Day Hormone Check
One Day Hormone Check DOB: Sex: F MRN: Order Number: Completed: Received: Collected: Salivary Hormone Results Estradiol pmol/l >3330.0 Testosterone pmol/l
More information8605 SW Creekside Place Beaverton, OR Phone: Fax: Height 5 ft 8 in BMI Weight 154 lb
TEST REPORT 218 8 2 2 SB Ordering Provider: Jane Getuwell, MD 865 SW Creekside Place Beaverton, OR 978 Phone: 53-466-2445 Fax: 53-466-1636 Samples Received 8/2/218 Report Date 8/8/218 Samples Collected
More informationTestosterone and PDE5 inhibitors in the aging male
Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
More informationTherapeutic Cohort Results
Patient: PAGE LOVE DOB: January 11, 1983 Sex: F MRN: 1232704193 Order Number: J9020008 Completed: July 08, 2016 Received: July 02, 2016 Collected: July 01, 2016 Aum Healing Center Sarika Arora MD 332 Newbury
More informationCorporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
More informationDiagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes
Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine
More informationHormone Replacement Therapy For Men Consultation Information
Hormone Replacement Therapy For Men Consultation Information www.urologyaustin.com Biological Aging and Hormones As we age, a natural degeneration and aging of organs causes the levels of our hormones
More informationProfessor TTUHSC Dept of Family and Community Medicine
Stephen G. Dalton D.O. Adjunct Clinical Assistant Stephen G. Dalton D.O. Adjunct Clinical Assistant Professor TTUHSC Dept of Family and Community Medicine 1-The first hormone to become deficient in perimenopauseis
More informationTestosterone Injection / Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Testosterone Injection / Implant Page: 1 of 9 Last Review Date: December 5, 2014 Testosterone
More informationIan Eardley Department of Urology, Leeds Teaching Hospital Trust
Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Assessment of the man with ED Medical therapy for man with ED What to do when pills fail Sexual stimulus Neural pathways Neurotransmitter
More informationIndex. Note: Page numbers of article titles are in boldface type.
Urol Clin N Am 31 (2004) 379 387 Index Note: Page numbers of article titles are in boldface type. A Acinar proliferation, atypical small, as markers for risk of development of prostate cancer, 229 Acupuncture,
More informationAccession #: Patient: Jane Doe Convert to pdf, Save or PRINT >> ADRENAL CHECK
Page 1 of 5 Patient: Jane Doe Tel: (123) 456-7890 Email: test@test.com Sex: Female Age: 36 yr Date of Birth: 1980-12-12 Height: 5 ft 0 in Weight: 135 lbs Waist size: 30 in 1st day of last menses: Day 07,
More informationVitamin D: Conflict of Interest Statement Corporate. Outline 7/5/2016
Vitamin D: What s New and Not? Clifford J Rosen MD Maine Medical Center Research Institute rosenc@mmc.org Conflict of Interest Statement Corporate NO STOCKS or EQUITY Editor UpToDate, New England Journal
More information10 Essential Blood Tests PART 2
Presents 10 Essential Blood Tests PART 2 The Blood Chemistry Webinars With DR. DICKEN WEATHERBY Creator of the Blood Chemistry Software Heart Disease, Inflammation, & Essential Blood Tests #2 to #4: Fibrinogen,
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: December 8, 2017 Testosterone
More informationMetastatic disease. 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942
Prostate cancer Metastatic disease 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942 Impact of early prostate cancer 12 10 8 6 4 2 0 70-80 years 60-70 years
More informationHormonal Alterations in Heart Failure: Anabolic Impairment in Chronic Heart Failure Diagnostic, Prognostic and Therapeutic Issues
Hormonal Alterations in Heart Failure: Anabolic Impairment in Chronic Heart Failure Diagnostic, Prognostic and Therapeutic Issues Michele Arcopinto Antonio Cittadini Department of Translational Medical
More informationGP guide to testosterone replacement therapy in men
GP guide to testosterone replacement therapy in men SPL Mike Kirby FRCP Professor Mike Kirby describes how the diagnosis and treatment of test - osterone deficiency in primary care can lead to improved
More informationThe Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD
Februray, 2013 The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD Why/How my cancer is back after surgery and/or radiation? Undetected micro-metastatic disease (spreading) before local
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone
More informationTreatment of Advanced Prostate Cancer
Treatment of Advanced Prostate Cancer Wm. Kevin Kelly, DO Associate Professor of Medicine and Surgery Yale University Yale University School of Medicine Advanced Prostate Cancer Metastatic Cancer Prostate
More informationpresents with Ken Sekine, MD
presents Pioneering Technologies For Pellet Hormone Therapy Lifestyle Based Medicine A Primer for Clinicians with Ken Sekine, MD Dr. Sekine is a board certified OB-GYN who has been in private practice
More informationConsent for Testosterone Therapy-Men Revised 4/10/18
Consent for Testosterone Therapy in Men You have been diagnosed with or have an increased risk of having a hormone deficiency and your provider has recommended treatment with bio-identical hormone replacement
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by
More informationASPEN MOUNTAIN MEDICAL CENTER. Lab Health Fair
ASPEN MOUNTAIN MEDICAL CENTER Lab Health Fair GENERAL HEALTH PANEL: CMP CMP The Comprehensive Metabolic Panel is used as a broad screening tool to evaluate organ function and check for conditions such
More informationThe reality of LOH-symptoms
The reality of LOH-symptoms PRISM IV Bruges, Belgium September 25-26, 2014 Dr. Herman Leliefeld Androsmannenkliniek The Netherlands The reality of LOH symptoms male external & internal genitalia Testosterone
More informationOutcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
ORIGINAL ARTICLE Vol. 41 (6): 1167-1171, November. December, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0528 Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More information